You are here

Novo Nordisk

Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

Fierce Biotech

Thu, 11/18/21 - 10:54 am

Dicerna Pharmaceuticals

Novo Nordisk nears EU approval of obesity drug Wegovy

Pharmaforum

Fri, 11/12/21 - 10:34 am

Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct

Endpoints

Mon, 11/8/21 - 10:46 am

Demand for new obesity drug outstripping supply

Beckers Hospital Review

Wed, 11/3/21 - 11:29 pm

Judge rules HHS' letter enforcing 340B discounts was 'arbitrary'

Beckers Hospital Review

Tue, 11/2/21 - 11:51 pm

United Therapeutics

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Fierce Pharma

Tue, 10/19/21 - 10:50 am

pharma marketing

Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September's list of top TV ad spenders

Fierce Pharma

Mon, 10/18/21 - 10:49 pm

On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

Endpoints

Tue, 10/12/21 - 11:43 pm

Sciwind Biosciences

Novo Nordisk settles insulin pricing suit for $100M

Endpoints

Mon, 09/27/21 - 10:56 am

HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations

Endpoints

Fri, 09/24/21 - 12:00 pm

United Therapeutics

Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analysts

Fierce Pharma

Mon, 09/13/21 - 10:41 am

House committee questions Eli Lilly, Sanofi and Novo Nordisk as insulin prices remain 'unacceptably high'

Endpoints

Fri, 08/20/21 - 12:31 pm

Demand for Novo Nordisk's new weight-loss drug Wegovy outstripped early supply, analysts say

Fierce Pharma

Wed, 08/4/21 - 10:41 pm

Sanofi, Lilly, Novo and a trio of PBMs face racketeering claims over pricey insulin drugs

Fierce Pharma

Tue, 07/13/21 - 11:32 pm

Express Scripts

The top 15 blockbuster patent expirations coming this decade

Fierce Pharma

Mon, 07/12/21 - 11:08 am

Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion

Fierce Biotech

Mon, 07/12/21 - 10:40 am

ATTR amyloidosis

Obesity Drug's Promise Now Hinges On Insurance Coverage

NPR

Tue, 07/6/21 - 10:39 am

ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

Fierce Pharma

Sun, 06/27/21 - 10:57 pm

type 2 diabetes

Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease

Pharma Letter

Wed, 06/16/21 - 11:56 am

Lumen Bioscience

Former Emisphere investors sue over 'ill-timed' $1.8B sale to Novo Nordisk

Fierce Pharma

Tue, 06/15/21 - 11:24 pm

Pages